Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,855
  • Shares Outstanding, K 113,894
  • Annual Sales, $ 63,530 K
  • Annual Income, $ -160,930 K
  • EBIT $ -197 M
  • EBITDA $ -183 M
  • 60-Month Beta 2.02
  • Price/Sales 13.52
  • Price/Cash Flow N/A
  • Price/Book 0.52

Options Overview Details

View History
  • Implied Volatility 227.66% ( +43.93%)
  • Historical Volatility 121.39%
  • IV Percentile 87%
  • IV Rank 40.78%
  • IV High 541.64% on 12/12/24
  • IV Low 11.45% on 09/16/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 179
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 3,914
  • Open Int (30-Day) 4,951

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 8
  • High Estimate -0.39
  • Low Estimate -0.48
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4532 +0.81%
on 01/10/25
2.3100 -36.58%
on 12/11/24
-0.8150 (-35.75%)
since 12/10/24
3-Month
1.4532 +0.81%
on 01/10/25
3.5000 -58.14%
on 11/18/24
-1.4750 (-50.17%)
since 10/10/24
52-Week
1.4532 +0.81%
on 01/10/25
8.8300 -83.41%
on 03/07/24
-3.1050 (-67.94%)
since 01/10/24

Most Recent Stories

More News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.4650 (-12.28%)
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion

Fate Therapeutics reports positive results from FT819 study in lupus, showing effective B-cell depletion and favorable safety outcomes.Quiver AI SummaryFate Therapeutics, Inc. announced promising results...

FATE : 1.4650 (-12.28%)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

FATE : 1.4650 (-12.28%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.4650 (-12.28%)
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025

Bob Valamehr will become CEO of Fate Therapeutics on January 1, 2025, succeeding retiring Scott Wolchko.Quiver AI SummaryFate Therapeutics, a clinical-stage biopharmaceutical company focused on induced...

FATE : 1.4650 (-12.28%)
Fate Therapeutics Announces Leadership Transition

FATE : 1.4650 (-12.28%)
Fate Therapeutics to Present at Upcoming December Investor Conferences

FATE : 1.4650 (-12.28%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 30.40 (+0.56%)
CSTL : 30.25 (-7.55%)
FATE : 1.4650 (-12.28%)
SPRO : 0.9800 (-2.00%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 1.4650 (-12.28%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

FATE : 1.4650 (-12.28%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 1.7474
2nd Resistance Point 1.6862
1st Resistance Point 1.5756
Last Price 1.4650
1st Support Level 1.4038
2nd Support Level 1.3426
3rd Support Level 1.2320

See More

52-Week High 8.8300
Fibonacci 61.8% 6.0121
Fibonacci 50% 5.1416
Fibonacci 38.2% 4.2711
Last Price 1.4650
52-Week Low 1.4532

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar